Profile data is unavailable for this security.
About the company
Vera Therapeutics, Inc. is a late-stage biotechnology company. The Company is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. Its product candidate, atacicept, is a self-administered fusion protein that blocks both a B lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL) which stimulates B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases. The Company is also engaged in developing MAU868, a monoclonal antibody designed to neutralize infection with BK Virus, a polyomavirus that can have devastating consequences in certain settings such as kidney transplants. The Company is conducting a randomized, double-blind, placebo-controlled Phase 3 clinical trial in IgAN, which it refers to as ORIGIN 3, and completing the open label extension of its Phase 2b clinical trial in IgAN, which it refers to as ORIGIN 2b.
- Revenue in USD (TTM)0.00
- Net income in USD-95.99m
- Incorporated2016
- Employees51.00
- LocationVera Therapeutics Inc8000 Marina Boulevard,, Suite 120BRISBANE 94005United StatesUSA
- Phone+1 (650) 770-0077
- Fax+1 (302) 655-5049
- Websitehttps://veratx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sana Biotechnology Inc | 0.00 | -283.26m | 1.97bn | 328.00 | -- | 6.19 | -- | -- | -1.46 | -1.46 | 0.00 | 1.45 | 0.00 | -- | -- | 0.00 | -40.81 | -38.99 | -46.74 | -42.70 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -5.11 | -- | 112.71 | -- |
| Amphastar Pharmaceuticals Inc | 644.40m | 137.55m | 2.02bn | 1.76k | 15.94 | 3.10 | 11.35 | 3.13 | 2.59 | 2.59 | 12.16 | 13.30 | 0.5716 | 2.78 | 6.33 | 365,925.60 | 12.38 | 9.42 | 14.42 | 11.56 | 54.91 | 47.83 | 21.65 | 15.23 | 1.70 | 10.68 | 0.4799 | 0.00 | 29.14 | 16.94 | 50.51 | -- | -4.00 | -- |
| Keros Therapeutics Inc | 151.00k | -152.99m | 2.03bn | 136.00 | -- | 5.40 | -- | 13,469.29 | -5.19 | -5.19 | 0.0051 | 10.43 | 0.0005 | -- | 2.11 | 1,110.29 | -45.21 | -35.95 | -48.12 | -38.07 | -- | -- | -101,319.20 | -1,237.26 | -- | -- | 0.00 | -- | -- | -56.77 | -46.15 | -- | 62.57 | -- |
| Intellia Therapeutics Inc | 36.28m | -481.19m | 2.06bn | 526.00 | -- | 1.90 | -- | 56.70 | -5.42 | -5.42 | 0.4106 | 11.29 | 0.0257 | -- | 1.80 | 68,963.88 | -34.11 | -31.34 | -37.31 | -34.53 | -- | -- | -1,326.51 | -654.71 | -- | -- | 0.00 | -- | -30.40 | 3.57 | -1.48 | -- | 17.08 | -- |
| Maravai Lifesciences Holdings Inc | 288.95m | -119.03m | 2.06bn | 650.00 | -- | 4.94 | -- | 7.13 | -0.901 | -0.901 | 2.19 | 1.66 | 0.1533 | 3.15 | 2.99 | 444,530.80 | -7.34 | 12.67 | -9.75 | 15.46 | 48.52 | 74.79 | -47.89 | 37.32 | 7.41 | -0.3566 | 0.4134 | 0.00 | -67.28 | 18.47 | -154.05 | -- | 78.56 | -- |
| Kymera Therapeutics Inc | 78.59m | -146.96m | 2.06bn | 187.00 | -- | 4.73 | -- | 26.25 | -2.52 | -2.52 | 1.35 | 7.11 | 0.1333 | -- | 7.38 | 420,278.10 | -24.93 | -23.03 | -28.76 | -27.64 | -- | -- | -186.99 | -207.82 | -- | -- | 0.0065 | -- | 67.84 | -- | 5.07 | -- | 91.01 | -- |
| Deciphera Pharmaceuticals Inc | 163.36m | -194.94m | 2.08bn | 355.00 | -- | 5.80 | -- | 12.72 | -2.29 | -2.29 | 1.92 | 4.36 | 0.3522 | 0.1787 | 6.01 | 460,157.80 | -42.03 | -44.54 | -52.63 | -52.24 | 97.72 | -- | -119.34 | -245.88 | 3.59 | -- | 0.00 | -- | 21.87 | -- | -8.95 | -- | -7.11 | -- |
| TG Therapeutics Inc | 233.66m | 12.67m | 2.11bn | 264.00 | 967.42 | 12.89 | 163.73 | 9.03 | 0.0141 | 0.0141 | 1.61 | 1.06 | 0.8933 | -- | 9.15 | 885,087.10 | 4.84 | -62.87 | 6.09 | -80.06 | 93.95 | -- | 5.42 | -405.03 | 5.18 | 1.64 | 0.3842 | -- | 8,290.02 | 333.86 | 106.39 | -- | -- | -- |
| Vera Therapeutics Inc | 0.00 | -95.99m | 2.15bn | 51.00 | -- | 17.27 | -- | -- | -2.28 | -2.28 | 0.00 | 2.29 | 0.00 | -- | -- | 0.00 | -62.54 | -- | -74.10 | -- | -- | -- | -- | -- | -- | -- | 0.3291 | -- | -- | -- | -7.79 | -- | -- | -- |
| Arvinas Inc | 78.50m | -367.30m | 2.17bn | 445.00 | -- | 3.27 | -- | 27.65 | -6.62 | -6.62 | 1.45 | 9.71 | 0.061 | -- | 157.00 | 176,404.50 | -28.35 | -22.01 | -36.10 | -26.47 | -- | -- | -464.71 | -316.55 | -- | -- | 0.0012 | -- | -40.26 | 40.53 | -30.02 | -- | 0.4852 | -- |
| Dyne Therapeutics Inc | 0.00 | -235.94m | 2.18bn | 141.00 | -- | 17.04 | -- | -- | -3.94 | -3.94 | 0.00 | 1.49 | 0.00 | -- | -- | 0.00 | -100.10 | -52.81 | -120.31 | -57.45 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -40.36 | -- | 40.32 | -- |
| Guardant Health Inc | 563.95m | -479.45m | 2.19bn | 1.78k | -- | 13.80 | -- | 3.88 | -4.28 | -4.28 | 5.04 | 1.30 | 0.3321 | 4.00 | 6.06 | 317,002.80 | -28.23 | -22.26 | -31.99 | -24.59 | 59.74 | 64.62 | -85.02 | -97.07 | 6.24 | -12.04 | 0.8778 | -- | 25.45 | 44.14 | 26.76 | -- | 0.2786 | -- |
| Denali Therapeutics Inc | 330.53m | -145.22m | 2.20bn | 445.00 | -- | 2.07 | -- | 6.66 | -1.09 | -1.09 | 2.39 | 7.45 | 0.2529 | -- | -- | 742,766.30 | -11.11 | -14.98 | -13.37 | -17.71 | -- | -- | -43.94 | -104.50 | -- | -- | 0.00 | -- | 204.74 | 20.67 | 55.45 | -- | 30.70 | -- |
| Vericel Corp | 197.52m | -3.18m | 2.22bn | 314.00 | -- | 9.71 | 1,416.22 | 11.24 | -0.0684 | -0.0684 | 4.15 | 4.72 | 0.6304 | 4.26 | 3.77 | 629,031.90 | -1.02 | -3.07 | -1.17 | -3.50 | 68.64 | 67.87 | -1.61 | -4.49 | 4.21 | -- | 0.0004 | -- | 20.17 | 16.80 | 80.96 | -- | 59.35 | -- |
| Avidity Biosciences Inc | 9.56m | -212.22m | 2.29bn | 253.00 | -- | 3.82 | -- | 239.64 | -2.90 | -2.90 | 0.131 | 6.32 | 0.0151 | -- | -- | 37,786.56 | -33.49 | -31.61 | -37.40 | -34.45 | -- | -- | -2,219.88 | -1,540.50 | -- | -- | 0.00 | -- | 3.64 | 90.71 | -21.97 | -- | 143.89 | -- |
| Geron Corp | 237.00k | -184.13m | 2.31bn | 141.00 | -- | 8.64 | -- | 9,732.34 | -0.3246 | -0.3246 | 0.0004 | 0.455 | 0.0008 | -- | 0.0988 | 1,680.85 | -62.99 | -51.32 | -92.09 | -64.90 | -- | -- | -77,690.72 | -19,949.13 | -- | -- | 0.2484 | -- | -60.23 | -25.97 | -29.76 | -- | 120.29 | -- |
Data as of May 01 2024. Currency figures normalised to Vera Therapeutics Inc's reporting currency: US Dollar USD
43.03%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Commodore Capital LPas of 31 Dec 2023 | 5.45m | 9.92% |
| Kynam Capital Management LPas of 31 Dec 2023 | 3.65m | 6.65% |
| Fidelity Management & Research Co. LLCas of 31 Dec 2023 | 2.77m | 5.05% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 2.51m | 4.58% |
| SSgA Funds Management, Inc.as of 31 Dec 2023 | 2.18m | 3.97% |
| Eversept Partners LPas of 31 Dec 2023 | 1.91m | 3.49% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 1.56m | 2.85% |
| Pictet Asset Management SAas of 31 Dec 2023 | 1.33m | 2.42% |
| Woodline Partners LPas of 12 Feb 2024 | 1.14m | 2.08% |
| Schroder Investment Management Ltd.as of 31 Dec 2023 | 1.11m | 2.02% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
